✓ Editorial reviews of U.S. telehealth programs · Prices and dates shown on each page · Educational only — not medical advice
Drug Reference

Tirzepatide

Released: Last reviewed:

Dual GLP-1/GIP receptor agonist. Brand names: Mounjaro (T2D), Zepbound (chronic weight management; OSA in adults with obesity).

By Eli Lilly
Researched By
Dr. Parmis
Medical Researcher · Western University of Health Sciences
Medically Reviewed By
Dr. Jonathan Snipes, MD · Kim Callender, NP (FNP-BC)
Last medically reviewed: November 20, 2026 · This page is informational and does not constitute medical advice.

Tirzepatide overview

Dual GLP-1/GIP receptor agonist. Brand names: Mounjaro (T2D), Zepbound (chronic weight management; OSA in adults with obesity).

Tirzepatide at a glance

Manufacturer
Eli Lilly
FDA status
FDA-approved

Related pages

Key facts, checked November 20, 2026

Tirzepatide is the active ingredient in two FDA-approved brands: Zepbound for weight management and sleep apnea in adults (Zepbound label) and Mounjaro for type 2 diabetes in adults and children 10 and older (Mounjaro label). In SURMOUNT-1 (NEJM 2022), the 15 mg dose produced 20.9% average weight loss at 72 weeks under the treatment-regimen estimand, and in SURMOUNT-5 (NEJM 2025) tirzepatide produced 20.2% versus 13.7% with semaglutide. Compounded tirzepatide is not FDA-approved and was not tested in these trials, as FDA’s page on unapproved GLP-1 drugs explains.